What is the price of EQRx, Inc. (EQRX)

The price of EQRx, Inc. (EQRX) is $2.34

What is the market cap of EQRx, Inc. (EQRX)

The market cap of EQRx, Inc. (EQRX) is $728.90M

EQRx, Inc. (EQRX) Dividends

EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating therapies, predominantly for oncological (cancer) and immune-inflammatory conditions. The company's late-stage pipeline features two promising drug candidates in Phase III clinical trials: Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and Sugemalimab, an anti-programmed death-ligand 1 antibody aimed at treating Stage III and Stage IV NSCLC. Its broader developmental portfolio encompasses a range of additional clinical and pre-clinical assets. This portfolio includes Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor in Phase II trials for metastatic breast cancer; EQ176, an anti-programmed death-1 antibody undergoing Phase III development for primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor currently in various Phase I studies. Established in 2019, EQRx maintains its corporate headquarters in Cambridge, Massachusetts.

Year	Dividend (stock split adjusted)	Change
Not enough data for the provided dates.

Year

Dividend (stock split adjusted)

Change

Not enough data for the provided dates.

Year	Dividend	Change
Not enough data for the provided dates.

Year

Dividend

Change

Not enough data for the provided dates.

Company	Number of dividend payments	Country
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	64.00%	AU
Moderna, Inc. MRNA.US	0.00%	US
Lonza Group AG LONN.SW	0.00%	CH

Company

Number of dividend payments

Country